NCT06373861 Generating Advancements Through Longitudinal Analysis in X and Y Variations (GALAXY)
| NCT ID | NCT06373861 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Colorado, Denver |
| Condition | Sex Chromosome Aneuploidy |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2022-04-28 |
| Primary Completion | 2037-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2022-04-28 with a primary completion date of 2037-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
GALAXY is a registry research study that plans to learn more about individuals with X\&Y variations (also called sex chromosome aneuploidies) through collecting information from medical records.This includes genetic tests, imaging, medications, and more for hundreds of patients seen at a number of clinics across the US. The purpose of the GALAXY Registry is to collect and store this information with the overall goal to improve health outcomes in individuals with X\&Y variations and the care they receive.
Eligibility Criteria
Inclusion Criteria: 1. Genetically-confirmed diagnosis of a sex chromosome aneuploidy condition 2. Any age 3. Any gender 4. Informed consent for individuals \>18 years of age, parent/guardian permission for individuals \<18 or proxy-consent from legally authorized representative if impaired decision making Exclusion Criteria: a. Lack of documentation of genetic testing confirming SCA diagnosis
Contact & Investigator
Shanlee M Davis, MD, PhD
PRINCIPAL INVESTIGATOR
Children's Hospital Colorado
Frequently Asked Questions
Who can join the NCT06373861 clinical trial?
This trial is open to participants of all sexes, aged 0 Days or older, up to 100 Years, studying Sex Chromosome Aneuploidy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06373861 currently recruiting?
Yes, NCT06373861 is actively recruiting participants. Contact the research team at shanlee.davis@childrenscolorado.org for enrollment information.
Where is the NCT06373861 trial being conducted?
This trial is being conducted at Aurora, United States.
Who is sponsoring the NCT06373861 clinical trial?
NCT06373861 is sponsored by University of Colorado, Denver. The principal investigator is Shanlee M Davis, MD, PhD at Children's Hospital Colorado. The trial plans to enroll 5,000 participants.